SCHEMBL2382841

SCHEMBL2382841

Nc1nccc(COc2ccccc2N2CCN(C(=O)Nc3cccc(F)c3)CC2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.53
MAPT P10636 7/20 0.52
MAPK1 P28482 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
RAB9A P51151 1/20 0.48
MEN1 O00255 2/20 0.48
HTT P42858 2/20 0.48
KMT2A Q03164 2/20 0.48
TSHR P16473 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
GAA P10253 1/20 0.48
POLB P06746 3/20 0.47
FAAH O00519 2/20 0.47
GLA P06280 1/20 0.44
HTR1A P08908 1/20 0.44
HTR1D P28221 1/20 0.44
HTR1B P28222 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385620 0.90 MAPT (0.51) MAPTMAPK1L3MBTL1RAB9AMEN1
SCHEMBL12251171 0.90 MAPT (0.63) MAPTMAPK1L3MBTL1RAB9AMEN1
SCHEMBL2383066 0.89 TRPV1 (0.52) TRPV1MAPTNPSR1POLBFAAH
SCHEMBL2384230 0.88 MAPT (0.55) MAPTMAPK1L3MBTL1RAB9AMEN1
SCHEMBL2385067 0.88 MAPT (0.45) TRPV1MAPTMAPK1L3MBTL1MEN1
SCHEMBL2383034 0.86 MAPT (0.56) TRPV1MAPTMAPK1L3MBTL1RAB9A
SCHEMBL2386092 0.85 TRPV1 (0.47) TRPV1MAPTMAPK1L3MBTL1MEN1
SCHEMBL2384332 0.84 MAPT (0.50) MAPTMAPK1L3MBTL1RAB9AMEN1
SCHEMBL2384728 0.83 TRPV1 (0.51) TRPV1MAPTMEN1KMT2APOLB
SCHEMBL2385197 0.81 MAPT (0.49) TRPV1MAPTMAPK1L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US claimed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275952-A1 Tie-2 Modulators and Methods of Use TIE1, TEK, KDR TRPV1 4108/4885MAPT 2716/4885MAPK1 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.